Click here for an archive of Cramer's "Mad Money" recaps.
is a stock that could be a good trade and a good investment, Jim Cramer told viewers of his "Mad Money" TV show Friday.
The stock, which Cramer first recommended a year ago, is up a "cool 30%," Cramer said. And he expects it to go up even more.
On Nov. 14, the company is going to make a presentation in front of the Philadelphia Gaming Board to open up a slot parlor in Philadelphia, Cramer said.
It should get state approval, but even a favorable public sentiment should send the stock up.
If it does get approval, Trump could "shoot up" $4, he said.
Trump has become a "worthy casino stock," Cramer continued. It has put money back into its casinos by remodeling them, and it recently reported an upside surprise, he said.
Everywhere the casino company remodels, growth is coming back, Cramer said. "Renovations are beginning to attract high-quality players."
In addition, for years Atlantic City, where all the Trump casinos are located, "was a dingy environment," but now the city is starting to turn around.
With Jim Perry, Trump's CEO, putting on a great execution, with the turn in Atlantic City and with the possibility of the Philadelphia casino being built, Trump could be worth at least $32, Cramer said. Trump closed at $22.05 on Friday.
Cramer suggested getting into the stock before the company's meeting with the Gaming Board in November because "that's when the momentum should build."
"Buy it before Philadelphia Gaming Board decides whether it should open a slot parlor in Philadelphia," he said.
However, if market players can't buy Trump at a low price, he urged them not to buy it.
Remember that winter is "weary" in Atlantic City, Cramer said, so people might have an opportunity to buy the stock in January -- if they miss the November and December trade.
There are certain stocks that can make market players 50% of their gains, while other stocks in their portfolio "languish" Cramer said.
was one of the stocks that always brought people's portfolios higher. Cramer believes he has found another stock which should do the same --
Although MasterCard has already gone up dramatically, Cramer said he has suggested other stocks that have had big runs as well, such as
Research In Motion
People might have missed "40-odd points" in MasterCard, but he believes that this stock still has "major upside."
"The IPO was priced way, way too low, so forget that it has doubled," Cramer told viewers. "The stock should have opened at $60, maybe $70."
Moreover, MasterCard is an "irreplaceable franchise," he said. "When a company gets "demutualized," it becomes a knocking opportunity. That's what has happened at MasterCard."
Plus, not only does it have a "big opportunity in China," but also it "blew out" its earnings estimates with two major upside surprises, Cramer said.
MasterCard has "pure organic growth" and "earnings power," he said. "I think this goes to $150."
MasterCard closed at $89.20 on Friday.
Going over his game plan for next week, Cramer told viewers to buy
ahead of its Tuesday report.
He said he also likes
, as Warren Buffett is a buyer of this stock.
, Cramer said he likes
is going to report a bad quarter next week, but it should give positive year-over-year numbers, which is why Cramer has been buying it for his charitable trust,
Action Alerts PLUS, he said.
Regarding the drug stocks, he said the Street got "panicked" about price controls, which could cap profits.
"When institutions get really scared, millions and millions of drug-stock shares get sold," Cramer said.
And, as he believes that traders are not finished dumping these stocks, he suggested not getting in until there is an opening that "looks good and stays good."
"Wait for the institutions to finish selling," Cramer advised. "And when the stocks open up and go up for the rest of the day, you will know all the inventory has been cleaned out."
Wait until these stocks lift at the market's opening and lift all day, he stressed. Then it will be OK to buy.
Cramer welcomed Jonah Shacknai,
CEO, to the show and asked him to speak about his products.
The company just launched an antibiotic, Solodyn, last summer, the first antibiotic approved for moderate-to-severe acne, and "the market is loving it," Shacknai responded.
In addition, this week Medicis got approval from the Food and Drug Administration for Ziana, another acne drug which "could also be a blockbuster," Cramer said.
Also, Shacknai said he hopes to see the approval of Prolane, a third acne drug, soon.
Cramer called Medicis a "bull story between now and the end of year."
To view Cramer's interview with Jonah Shacknai, please click here.
Cramer was bullish on
Automatic Data Processing
Cramer was bearish on
For more of Cramer's insights during the Lightning Round, click here
Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by
At the time of publication, Cramer was long Sears and Marvell Technology.
Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for TheStreet.com, Inc., and CNBC, and a director and co-founder of TheStreet.com. All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of TheStreet.com or its affiliates, or CNBC, NBC UNIVERSAL or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither TheStreet.com, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or TheStreet.com is related to the specific opinions expressed by him on "Mad Money."
None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, TheStreet.com or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor TheStreet.com, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on TheStreet.com. The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in TheStreet.com, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.